Key terms
About HEPA
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest HEPA news
Apr 19
5:08pm ET
Hepion Pharmaceuticals falls 42% after wind down of ASCEND-NASH trial
Apr 19
5:00pm ET
Hepion Pharmaceuticals trading resumes
Apr 19
4:31pm ET
Hepion Pharmaceuticals initiates wind-down activities in Phase 2b ‘ASCEND-NASH’
Apr 19
4:25pm ET
Hepion Pharmaceuticals trading halted, news pending
Mar 06
8:37am ET
Hepion Pharmaceuticals appoints Purcell to board of directors
Feb 16
9:12am ET
Hepion Pharmaceuticals Bolsters Capital with Equity Deals
Feb 16
8:06am ET
Hepion Pharmaceuticals announces exercise of warrants for $2M in gross proceeds
No recent press releases are available for HEPA
HEPA Financials
Key terms
Ad Feedback
HEPA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
HEPA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range